| scholarly article | Q13442814 |
| P2093 | author name string | W. F. Blakemore | |
| K. A. Irvine | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1464-1477 | |
| P577 | publication date | 2008-01-29 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Remyelination protects axons from demyelination-associated axon degeneration | |
| P478 | volume | 131 |
| Q40025304 | 17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice |
| Q37062840 | AMP-activated protein kinase signaling protects oligodendrocytes that restore central nervous system functions in an experimental autoimmune encephalomyelitis model |
| Q38870619 | Activation of FXR pathway does not alter glial cell function |
| Q37129632 | Activation of oligodendroglial Stat3 is required for efficient remyelination. |
| Q48110813 | Activin receptors regulate the oligodendrocyte lineage in health and disease. |
| Q57156349 | Activity-dependent central nervous system myelination throughout life |
| Q97516678 | Acute Cellular and Functional Changes With a Combinatorial Treatment of Ion Channel Inhibitors Following Spinal Cord Injury |
| Q40191448 | Acutely damaged axons are remyelinated in multiple sclerosis and experimental models of demyelination. |
| Q46822486 | Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte regeneration and remyelination. |
| Q39005318 | Advanced neuroimaging to quantify myelin in vivo: Application to mild TBI. |
| Q22251261 | Alzheimer's disease as homeostatic responses to age-related myelin breakdown |
| Q63741065 | An in vitro model for studying CNS white matter: functional properties and experimental approaches |
| Q35999574 | An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination |
| Q37743241 | Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. |
| Q35126104 | Axonal damage in multiple sclerosis. |
| Q35909149 | Axonal thinning and extensive remyelination without chronic demyelination in spinal injured rats |
| Q49272997 | C-Phycocyanin and Phycocyanobilin as Remyelination Therapies for Enhancing Recovery in Multiple Sclerosis and Ischemic Stroke: A Preclinical Perspective |
| Q26747242 | CNS Remyelination and the Innate Immune System |
| Q36067861 | CXCL12 Gene Therapy Ameliorates Ischemia-Induced White Matter Injury in Mouse Brain |
| Q47619959 | Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases |
| Q47734306 | Cell therapy for spinal cord injury with olfactory ensheathing glia cells (OECs). |
| Q90732168 | Central Nervous System Remyelination: Roles of Glia and Innate Immune Cells |
| Q42027997 | Central nervous system remyelination in culture--a tool for multiple sclerosis research |
| Q36501618 | Cervical spinal demyelination with ethidium bromide impairs respiratory (phrenic) activity and forelimb motor behavior in rats |
| Q55129108 | Characterization of a murine mixed neuron-glia model and cellular responses to regulatory T cell-derived factors. |
| Q42594603 | Class 3 semaphorins influence oligodendrocyte precursor recruitment and remyelination in adult central nervous system |
| Q47276728 | Clinical implications of myelin regeneration in the central nervous system |
| Q35081711 | Components of myelin damage and repair in the progression of white matter pathology after mild traumatic brain injury |
| Q36504051 | Cortical remyelination: a new target for repair therapies in multiple sclerosis. |
| Q54363020 | Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice. |
| Q37633504 | Creatine Enhances Mitochondrial-Mediated Oligodendrocyte Survival After Demyelinating Injury |
| Q38105989 | Cuprizone-induced demyelination as a tool to study remyelination and axonal protection |
| Q47549630 | Deficient Surveillance and Phagocytic Activity of Myeloid Cells Within Demyelinated Lesions in Ageing Mice Visualized by Ex Vivo Live Multiphoton Imaging. |
| Q35592803 | Demyelination and remyelination in anatomically distinct regions of the corpus callosum following cuprizone intoxication |
| Q36090107 | Demyelination as a rational therapeutic target for ischemic or traumatic brain injury |
| Q44651982 | Demyelination versus remyelination in progressive multiple sclerosis. |
| Q40360370 | Dietary cholesterol promotes repair of demyelinated lesions in the adult brain |
| Q92814401 | Differential Expression of miRNAs and Behavioral Change in the Cuprizone-Induced Demyelination Mouse Model |
| Q91393063 | Differential effects of glucose deprivation on the survival of fetal versus adult neural stem cells-derived oligodendrocyte precursor cells |
| Q50249375 | Diosgenin promotes oligodendrocyte progenitor cell differentiation through estrogen receptor-mediated ERK1/2 activation to accelerate remyelination |
| Q39375830 | Drug discovery for remyelination and treatment of MS. |
| Q43246648 | Dysmyelinated axons in shiverer mice are highly vulnerable to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity |
| Q52651173 | Early netrin-1 expression impairs central nervous system remyelination. |
| Q37867334 | Enhancing remyelination in disease--can we wrap it up? |
| Q64237591 | ErbB receptor signaling directly controls oligodendrocyte progenitor cell transformation and spontaneous remyelination after spinal cord injury |
| Q38180157 | Established and novel disease-modifying treatments in multiple sclerosis |
| Q37167704 | Extensive remyelination of the CNS leads to functional recovery |
| Q35010204 | Extracellular acidic pH inhibits oligodendrocyte precursor viability, migration, and differentiation |
| Q35279577 | FGF8 activates proliferation and migration in mouse post-natal oligodendrocyte progenitor cells |
| Q37989903 | FTY720 on the way from the base camp to the summit of the mountain: relevance for remyelination |
| Q92915291 | Feline irradiated diet-induced demyelination; a model of the neuropathology of sub-acute combined degeneration? |
| Q41020735 | Fibroblast growth factor signalling in multiple sclerosis: inhibition of myelination and induction of pro-inflammatory environment by FGF9. |
| Q38366783 | From demyelination to remyelination: the road toward therapies for spinal cord injury |
| Q51400507 | Functional and molecular evidence of myelin- and neuroprotection by thyroid hormone administration in experimental allergic encephalomyelitis. |
| Q47814848 | GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis |
| Q33851531 | Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination |
| Q35795587 | Glia Disease and Repair-Remyelination |
| Q48120989 | Grey matter OPCs are less mature and less sensitive to IFNγ than white matter OPCs: consequences for remyelination |
| Q37739872 | IL4I1 augments CNS remyelination and axonal protection by modulating T cell driven inflammation |
| Q37459641 | Impact of sex steroids on neuroinflammatory processes and experimental multiple sclerosis |
| Q31045707 | In vivo quantification of demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy. |
| Q30501593 | Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. |
| Q37785417 | Inflammation in Neurological Disorders: A Help or a Hindrance? |
| Q54383932 | Inhibition of CNS remyelination by the presence of semaphorin 3A. |
| Q90608717 | Inhibition of Piezo1 attenuates demyelination in the central nervous system |
| Q34974090 | Limited TCF7L2 expression in MS lesions. |
| Q36090219 | Longitudinal Evaluation of Visual Function in Multiple Sclerosis |
| Q88223331 | MMP7 cleaves remyelination-impairing fibronectin aggregates and its expression is reduced in chronic multiple sclerosis lesions |
| Q48001723 | Mechanisms of lysophosphatidylcholine-induced demyelination: A primary lipid disrupting myelinopathy |
| Q35173135 | Mediators of oligodendrocyte differentiation during remyelination |
| Q37608080 | Modeling multiple sclerosis in laboratory animals. |
| Q47677846 | Multiple Sclerosis: Basic and Clinical. |
| Q61861830 | Multiple sclerosis |
| Q38993743 | Multiple sclerosis animal models: a clinical and histopathological perspective |
| Q37979969 | Multiple sclerosis: neuroprotective alliance of estrogen-progesterone and gender |
| Q57986078 | Muscarinic receptor MR signaling prevents efficient remyelination by human and mouse oligodendrocyte progenitor cells |
| Q50477254 | Myelin inhibits oligodendroglial maturation and regulates oligodendrocytic transcription factor expression. |
| Q44942078 | Myelin loss and oligodendrocyte pathology in white matter tracts following traumatic brain injury in the rat. |
| Q33772195 | Myelin recovery in multiple sclerosis: the challenge of remyelination |
| Q37929620 | Myelin regeneration in multiple sclerosis: targeting endogenous stem cells |
| Q38718081 | Myelin regulatory factor drives remyelination in multiple sclerosis |
| Q60921577 | Myelination in Multiple Sclerosis Lesions Is Associated with Regulation of Bone Morphogenetic Protein 4 and Its Antagonist Noggin |
| Q43078106 | NG2-proteoglycan-dependent contributions of oligodendrocyte progenitors and myeloid cells to myelin damage and repair |
| Q48743494 | Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. |
| Q38632088 | Network-Based Genomic Analysis of Human Oligodendrocyte Progenitor Differentiation |
| Q39906289 | Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury. |
| Q48284501 | Neuregulin-1 promotes remyelination and fosters a pro-regenerative inflammatory response in focal demyelinating lesions of the spinal cord. |
| Q37493548 | Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis |
| Q54457597 | Neurofilament-tubulin binding site peptide NFL-TBS.40-63 increases the differentiation of oligodendrocytes in vitro and partially prevents them from lysophosphatidyl choline toxiciy. |
| Q37794273 | Neuromyelitis optica (NMO)--an autoimmune disease of the central nervous system (CNS). |
| Q37462045 | Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation |
| Q37164200 | Neuroplasticity and functional recovery in multiple sclerosis |
| Q37419064 | Neuroprotection and neuroregeneration in multiple sclerosis |
| Q38952007 | Neuroprotection by central nervous system remyelination: Molecular, cellular, and functional considerations |
| Q34992053 | Neurotrophin-3 targets the translational initiation machinery in oligodendrocytes |
| Q89586468 | Niacin-mediated rejuvenation of macrophage/microglia enhances remyelination of the aging central nervous system |
| Q27313149 | Nogo receptor inhibition enhances functional recovery following lysolecithin-induced demyelination in mouse optic chiasm |
| Q48226160 | Nogo-A antibodies enhance axonal repair and remyelination in neuro-inflammatory and demyelinating pathology. |
| Q38878763 | Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination. |
| Q34253257 | Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination |
| Q38609231 | Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis |
| Q48342467 | Oligodendroglial fibroblast growth factor receptor 1 gene targeting protects mice from experimental autoimmune encephalomyelitis through ERK/AKT phosphorylation. |
| Q89766748 | Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination |
| Q28486241 | Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation |
| Q43270590 | P2Y12 receptor protein in cortical gray matter lesions in multiple sclerosis |
| Q30835804 | Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging |
| Q47928247 | Pericytes modulate myelination in the central nervous system |
| Q47739408 | Peroxisome proliferator-activated receptor γ (PPARγ): A master gatekeeper in CNS injury and repair |
| Q50501021 | Platelet-derived growth factor-responsive neural precursors give rise to myelinating oligodendrocytes after transplantation into the spinal cords of contused rats and dysmyelinated mice. |
| Q92129018 | Polarizing receptor activation dissociates fibroblast growth factor 2 mediated inhibition of myelination from its neuroprotective potential |
| Q92535375 | Progressive multiple sclerosis: from pathophysiology to therapeutic strategies |
| Q27010398 | Promoting remyelination in multiple sclerosis-recent advances |
| Q41872258 | Promoting return of function in multiple sclerosis: An integrated approach |
| Q37212029 | Prostacyclin promotes oligodendrocyte precursor recruitment and remyelination after spinal cord demyelination |
| Q47663969 | Protease activated receptor 2 controls myelin development, resiliency and repair |
| Q34101668 | Quantification of increased cellularity during inflammatory demyelination. |
| Q49986398 | Regenerating CNS myelin - from mechanisms to experimental medicines. |
| Q50428928 | Regenerative Medicine: Advances from Developmental to Degenerative Diseases. |
| Q46521481 | Regional Myelin and Axon Damage and Neuroinflammation in the Adult Mouse Brain After Long-Term Postnatal Vanadium Exposure |
| Q64105817 | Regulation of Myelination by Exosome Associated Retinoic Acid Release from NG2-Positive Cells |
| Q38261543 | Remyelinating strategies in multiple sclerosis |
| Q37524562 | Remyelination - An effective means of neuroprotection. |
| Q64461676 | Remyelination in multiple sclerosis |
| Q97678560 | Remyelination in multiple sclerosis: from basic science to clinical translation |
| Q38364826 | Remyelination in multiple sclerosis: what do we know and where are we going? |
| Q30040587 | Remyelination in the CNS: from biology to therapy |
| Q83691347 | Remyelination is altered by bone morphogenic protein signaling in demyelinated lesions |
| Q36673233 | Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin |
| Q39420410 | Remyelination therapies: a new direction and challenge in multiple sclerosis |
| Q26824246 | Remyelination therapy for multiple sclerosis |
| Q38814687 | Remyelination: A Potential Therapeutic Strategy for Alzheimer's Disease? |
| Q85887014 | Reproducibility of multifocal visual evoked potential and traditional visual evoked potential in normal and multiple sclerosis eyes |
| Q37735773 | Role of cytokines as mediators and regulators of microglial activity in inflammatory demyelination of the CNS. |
| Q38072291 | Signalling pathways that inhibit the capacity of precursor cells for myelin repair |
| Q31140002 | Slow expansion of multiple sclerosis iron rim lesions: pathology and 7 T magnetic resonance imaging |
| Q82602601 | Slowly Progressive Axonal Degeneration in a Rat Model of Chronic, Nonimmune-Mediated Demyelination |
| Q37747349 | Stem cells in genetic myelin disorders |
| Q38784277 | Targeting human oligodendrocyte progenitors for myelin repair |
| Q37689081 | Temporal dynamics of myelination in the zebrafish spinal cord |
| Q30871067 | Thalamus pathology in multiple sclerosis: from biology to clinical application. |
| Q38658419 | The Role of the Oligodendrocyte Lineage in Acute Brain Trauma. |
| Q90269080 | The active contribution of OPCs to neuroinflammation is mediated by LRP1 |
| Q93380023 | The adult oligodendrocyte can participate in remyelination |
| Q50559743 | The advancement of human pluripotent stem cell-derived therapies into the clinic. |
| Q35984483 | The axon-glia unit in white matter stroke: mechanisms of damage and recovery. |
| Q35648148 | The myelin mutants as models to study myelin repair in the leukodystrophies |
| Q38111421 | The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment. |
| Q34468304 | The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis. |
| Q41958515 | The sphingosine 1-phosphate receptor agonist FTY720 is neuroprotective after cuprizone-induced CNS demyelination |
| Q89851555 | Therapeutic repair for spinal cord injury: combinatory approaches to address a multifaceted problem |
| Q46273126 | Thin myelin sheaths as the hallmark of remyelination persist over time and preserve axon function |
| Q38769752 | Timing of Future Remyelination Therapies and Their Potential to Stop Multiple Sclerosis Progression. |
| Q92998731 | Tracking the evolution of CNS remyelinating lesion in mice with neutral red dye |
| Q92300904 | Transforming growth factor-beta renders ageing microglia inhibitory to oligodendrocyte generation by CNS progenitors |
| Q39762323 | Transplanted neural precursors enhance host brain-derived myelin regeneration |
| Q38125123 | Treatment trials in progressive MS--current challenges and future directions |
| Q37972980 | White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis |
| Q37353898 | Zebrafish myelination: a transparent model for remyelination? |
| Q55114533 | cxcl12-engineered endothelial progenitor cells enhance neurogenesis and angiogenesis after ischemic brain injury in mice. |
| Q37017296 | α-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy |
Search more.